Utah Governor and BioUtah Recognize Co-Diagnostics Following Saudi Arabia Joint Venture

Utah Governor Spencer Cox joined BioUtah President and CEO Kelvyn Cullimore in recognizing Co-Diagnostics, Inc. following the company's announcement of forming CoMira Diagnostics, a joint venture in the Kingdom of Saudi Arabia. The recognition ceremony highlighted Co-Diagnostics' international expansion and its representation of Utah's life sciences sector on the global stage. Governor Cox emphasized that Co-Diagnostics exemplifies Utah-born companies competing internationally, with their expansion across the Middle East and North Africa regions demonstrating the strength of Utah's life sciences industry and the determination of local entrepreneurs.

Cullimore noted that BioUtah takes pride in counting Co-Diagnostics among its Elite members, stating that the recent signing of a definitive joint venture agreement with a company in Saudi Arabia further confirms Co-Diagnostics' expanding leadership and global presence. The joint venture represents a significant milestone for the Utah-based molecular diagnostics company, which develops advanced diagnostic tests using its patented platform technology. The company's technologies are utilized for tests designed to detect and analyze nucleic acid molecules, including applications beyond infectious disease detection.

The recognition event underscored the growing importance of Utah's life sciences community, which BioUtah describes as one of the fastest growing in the United States. Co-Diagnostics' expansion into Saudi Arabia through the CoMira Diagnostics joint venture represents not only business growth but also the potential for increased global healthcare impact through advanced diagnostic technologies. The company's proprietary technology is also being developed for its Co-Dx PCR at-home and point-of-care platform, though this remains subject to regulatory review and is not currently available for sale. This international expansion follows the company's pattern of global engagement and technological innovation in the molecular diagnostics field.